Pentixapharm Holding AG

Pentixapharm Holding has published the new total number of voting rights pursuant to §41 WpHG. The change is due to the issuance of subscription shares; the total now amounts to 35,815,689 voting rights, of which none are multiple voting rights. The notification was transmitted for Europe-wide dissemination (30.07.2026). » Mere på de.investing.com

Pentixapharm has fully placed 11.0 million new shares at €1.85 each, raising about €20.4 million gross. The proceeds are intended primarily to support the PANDA phase‑III approval study for PentixaFor as a non‑invasive diagnostic method, as well as US activities, production and supply chains. The full placement signals market confidence and improves the negotiating position for potential licensing or partnership deals, although the phase‑III study risk remains. » Mere på finanzen.net

Pentixapharm has placed 11.0 million new shares at €1.85, raising around €20.4 million in gross proceeds. The funds are intended primarily to finance the PANDA phase‑3 regulatory study, as well as US expansion and strengthening of manufacturing and supply chains. The full placement removes the previously central financing uncertainty and increases the chances of licensing deals before the study is completed. » Mere på finanzen.net